ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ANALYSIS

Antimicrobial Susceptibility Testing Market, By Product Type (Manual Antimicrobial Susceptibility Testing Products, Automated Laboratory Instruments, and Consumables), By Application (Antibacterial, Antifungal, Anti-parasitic, and Antiviral), By Method (Disk Diffusion, Rapid Automated AST, Broth Dilution, Gradient Diffusion, and Genotypic Methods), By End User (Hospitals, Pathology/Diagnostic Laboratories, Research and Academic Institutes, Pharmaceutical and Biotechnology Companies, and Contract Research Organizations), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : May 2024
Code : CMI2449
Pages :258
Formats :
Excel and PDF
Industry : Clinical Diagnostic

Market Challenge – High Price of Antimicrobial Susceptibility Testing Systems

Automated antimicrobial susceptibility testing systems are equipped with highly advanced features and have high prices. The automated antimicrobial susceptibility testing systems have several advantages such as reduced detection time, accuracy of testing, and others. However, the high price of such systems may act as a restraint for the global antimicrobial susceptibility testing market growth. For instance, according to an article published by the National Center for Biotechnology Information, a series of databases relevant to biotechnology and biomedicine, in July 2020, the high price of molecular testing for antimicrobial susceptibility forms an efficient barrier for the installation of new technologies. According to the same source, testing costs also include those associated with clinical sampling and cultivation in microbiology labs, the processes that are carried out before antimicrobial susceptibility testing (AST). The roughly estimated total cost for mass spectrometry-based AST is USD 83.3(€ 79) per patient, when the cost of the MALDI-TOF device, reagents, pharmacist time, and the antimicrobial stewardship program are pooled together.

Market Opportunity – Adoption of Molecular Diagnostic Technology for antimicrobial susceptibility testing

Adoption of molecular diagnostic technology for antimicrobial susceptibility testing could provide great opportunities in the global antimicrobial susceptibility testing market. Technologies like polymerase chain reaction (PCR) and DNA microarrays allow for rapid, comprehensive, and accurate identification of pathogens as well as direct detection of resistant genes from patient samples. This enables clinicians to prescribe the most effective therapies within the day instead of waiting 2-3 days for culture-based test results.